Accéder au contenu
Merck

Tonsillopharyngitis: evaluation of short-term treatment with cefuroxime axetil versus standard 10-day penicillin V therapy.

The British journal of clinical practice (1995-01-01)
P Gehanno, D Chichie
RÉSUMÉ

Recent resurgence in serious streptococcal infections and rising failure rates with the standard 10-day course of therapy with penicillin V for group A beta-haemolytic streptococcus (GABHS)-associated tonsillopharyngitis (pharyngitis and/or tonsillitis) have heightened interest in alternative treatments for this infection. Reasons for failure of the standard therapy include penicillin tolerance, increased virulence of GABHS strains, inactivation by beta-lactamase, and poor compliance. Short, 4-5-day courses with oral cephalosporins, such as cefuroxime axetil, have recently proven to be effective alternatives. Cefuroxime axetil provides resolution of clinical symptoms and fever within 2.5 days of onset of therapy, and its short course of treatment may improve compliance.

MATÉRIAUX
Référence du produit
Marque
Description du produit

USP
Cefuroxime Axetil, United States Pharmacopeia (USP) Reference Standard
Supelco
Cefuroxime, VETRANAL®, analytical standard
Cefuroxime Axetil, European Pharmacopoeia (EP) Reference Standard